This alliance will utilize Tranzyme’s TExT (Tranz Expression Technology) in support of the ABC Transporter chemogenomic program at Active Pass.
Under this collaboration, Active Pass will provide multiple sets of ABC transporter gene sequences, a family of molecular pumps found in the membranes of all cells.
Tranzyme will deliver these genes into mammalian cells and express and purify the proteins using its gene expression technology (TExT). Commenting on the collaboration, Peter B. Reiner, President & CEO of Active Pass Pharmaceuticals, stated, “Combining Tranzyme’s technology with our existing suite of ABC transporter gene sequences is a key step in advancing our ChemoGenomic strategy.”
“Tranzyme is delighted at the opportunity to work with Active Pass Pharmaceuticals, a company with cutting edge expertise in the area of ABC transporter genomics,” said Vipin K. Garg, Tranzyme’s President & CEO.
“Our scientists look forward to applying Tranzyme’s skills in mammalian cell cloning and protein expression to the exploitation by Active Pass of ABC transporters as targets for novel therapeutics.” Tranzyme, Inc. engaged in the development of proprietary technologies for applied genomics, proteomics, and drug discovery.
Tranzyme has developed proprietary molecular approaches in genetic engineering, gene transfer, and protein expression with broad applicability.
Active Pass Pharmaceuticals principal activity is the discovery and early clinical development of novel drugs which target abc transporters, a family of molecular pumps found throughout the body.